MedTrace Logo

POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma

NCT02466399 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-11-16

Study results available
· View outcomes & findings →

Summary

This is an open-label, randomized, multi-center, active-controlled parallel-comparison of POLAT-001 to latanoprost ophthalmic solution in patients with ocular hypertension and primary open-angle glaucoma.

Conditions

Interventions

DRUG

POLAT-001

Subconjunctival injection

DRUG

Latanoprost ophthalmic solution

Latanoprost ophthalmic solution q.d., evening

Sponsors & Collaborators

  • Peregrine Ophthalmic

    lead INDUSTRY

Principal Investigators

  • Tina T Wong, MD, Ph.D. · Peregrine Ophthalmic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02466399 on ClinicalTrials.gov